Wednesday, September 28, 2022
News
NEWS HOME
PRN INDIA
Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS
  SocialTwist Tell-a-Friend  
   

EMA accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to 150 days

Pharming is on track to submit its Marketing Authorisation Application for leniolisib in H2 2022

LEIDEN, the Netherlands, Aug. 1, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted an accelerated assessment for the Marketing Authorisation Application (MAA) for leniolisib. Leniolisib has been studied for the treatment of activated PI3K delta syndrome (APDS), a rare primary immunodeficiency, in adults and adolescents age 12 or older in the European Economic Area (EEA). Pharming is on track and plans to submit its MAA for leniolisib to the EMA in October 2022.

Pharming Group logo

Accelerated assessment reduces the timeframe for the CHMP to review an MAA from 210 days to 150 days. The EMA will grant, upon request, accelerated assessment of an MAA if they decide the product is of major interest for public health and therapeutic innovation.

The clinical development for leniolisib includes positive data from a Phase II/III study of the product, which met both its co-primary endpoints in the target patient population of evaluated reduction in lymph node size and correction of immunodeficiency. The primary efficacy results demonstrated clinical efficacy of leniolisib over placebo with a statistically significant reduction from baseline in the log10 transformed sum of product of diameters (SPD) in the index lymphadenopathy lesions (p=0.0012) and normalization of immune dysfunction, as evidenced by increased proportion of naïve B cells from baseline (p<0.0001). The shrinking of lymphadenopathy lesions and increased proportion of naïve B cells are important in patients as they indicate a reduction in APDS disease markers.

In the study, leniolisib was generally well-tolerated, with the majority of reported adverse events in both treatment groups classified as mild. There were no adverse events that led to discontinuation of study treatment, there were no deaths, and the incidence of serious adverse events (SAEs) was lower in the leniolisib group than the placebo group. None of the SAEs were suspected to be related to study treatment.

Anurag Relan, Chief Medical Officer of Pharming, commented:

"The acceptance of an accelerated regulatory review for leniolisib underlines the high unmet need for patients with APDS, with the product potentially being the first approved treatment for this rare disease. This is an important milestone for the APDS community and for Pharming and is built on the successful Phase II/III data, which we first reported in February 2022. We remain focused on progressing leniolisib through the regulatory review process, with our MAA on track for submission in October of this year, as we seek to make this important new product available to immunologists, hematologists, and their patients in Europe."

About Activated Phosphoinositide 3-Kinase δ Syndrome (APDS)

APDS is a rare primary immunodeficiency that affects approximately one to two people per million. Also known as PASLI, it is caused by variants in either of two genes, PIK3CD or PIK3R1, that regulate maturation of white blood cells. Variants of these genes lead to hyperactivity of the PI3Kδ (phosphoinositide 3-kinase delta) pathway.1,2 Balanced signaling in the PI3Kδ pathway is essential for physiological immune function. When this pathway is hyperactive, immune cells fail to mature and function properly, leading to immunodeficiency and dysregulation.1,3 APDS is characterized by severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy.4,5 Because these symptoms can be associated with a variety of conditions, including other primary immunodeficiencies, people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay.6 As APDS is a progressive disease, this delay may lead to an accumulation of damage over time, including permanent lung damage and lymphoma.4-7 The only way to definitively diagnose this condition is through genetic testing.

About Leniolisib

Leniolisib is a small-molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA PI3K with immunomodulating and potentially anti-neoplastic activities. Leniolisib inhibits the production of phosphatidylinositol-3-4-5-trisphosphate (PIP3). PIP3 serves as an important cellular messenger specifically activating AKT (via PDK1) and regulates a multitude of cell functions such as proliferation, differentiation, cytokine production, cell survival, angiogenesis, and metabolism. Unlike PI3Kα and PI3Kβ, which are ubiquitously expressed, PI3Kẟ and PI3Kγ are expressed primarily in cells of hematopoietic origin. The central role of PI3Kẟ in regulating numerous cellular functions of the adaptive immune system (B-cells and, to a lesser extent, T cells) as well as the innate immune system (neutrophils, mast cells, and macrophages) strongly indicates that PI3Kẟ is a valid and potentially effective therapeutic target for several immune diseases. To date, leniolisib has been well tolerated during both the Phase 1 first-in-human trial in healthy subjects and the Phase II/III registration-enabling study.

About Pharming Group N.V.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit www.pharming.com.

Forward-looking Statements

This press release contains forward-looking statements, including with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, Pharming's ability to overcome the challenges posed by the COVID-19 pandemic to the conduct of its business, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2021 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release.

Inside Information

This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

References

1. Lucas CL, et al. Nat Immunol. 2014;15:88-97.
2. Elkaim E, et al. J Allergy Clin Immunol. 2016;138(1):210-218.
3. Nunes-Santos C, et al. J Allergy Clin Immunol. 2019;143(5):1676-1687.
4. Coulter TI, et al. J Allergy Clin Immunol. 2017;139(2):597-606.
5. Maccari ME, et al. Front Immunol. 2018;9:543.
6. Jamee M, et al. Clin Rev Allergy Immunol. 2020;59(3):323-333.
7. Condliffe AM, Chandra A. Front Immunol. 2018;9:338.

Logo - https://mma.prnewswire.com/media/1778344/Pharming_Group_NV_Logo.jpg

More News by PR Newswire India

GLOBAL STANDARD OF CARE SIGNIFICANTLY REDUCED DUE TO MENTAL HEALTH OF HEALTHCARE WORKERS

Vieworks to Showcase Industrial Cameras and Lenses at VISION 2022

Eviation's Alice Achieves Milestone with First Flight of All-Electric Aircraft

SAUDI ARABIA IS THE FASTEST GROWING TOURISM DESTINATION IN THE G20

Internet sensation Khaby Lame announced as QNB Group's Official FIFA World Cup Qatar 2022™ Brand Ambassador

GIGABYTE Launches Z790 Series Motherboards Supporting Dual-Generation Intel Processors

Deltek Research to Unveil Top Federal Contracting Opportunities for 2023

ViewSonic Unveils Industry-First Foldable 135" All-in-One LED Display Solution Kit

NEOM Tech & Digital Company steps into the future as 'Tonomus'

Global Fab Equipment Spending Forecast to Reach All-Time High of Nearly $100 Billion in 2022, SEMI Reports

Kohler India celebrates their 10th Year of Pecha Kucha in New Delhi, India

U.S. Soy Sustainability Assurance Protocol (SSAP) Certificates Can Now Be Transferred

CP KELCO PARTNERS WITH EXOPOLYMER TO BRING NEXT-GENERATION FUNCTIONAL BIOPOLYMERS TO MARKET

Old Mission Selects Solace to Support Rapid Growth of Business through Event-Driven Architecture

GIGABYTE Launches Four AMD X670 Motherboards for New Ryzen 7000 Processors

SRK Knowledge Foundation announces transformational partnership with The Global Network for Zero

LyondellBasell Announces Organizational Changes

HarperCollins India presents HAPPILY INSURED: Your Guide to Understanding Insurance and Leading a Stress-Free Life by Kapil Mehta

Hisense Unveils Its FIFA World Cup Qatar 2022™ TVC "Perfect Match" Ahead of Tournament

The 2022 4th "My China Story" International Short Video Competition Award Ceremony was held in Hangzhou, Zhejiang

Light up the festive season with 'Sale Dhamaka' on MSI's laptop range

GLOBAL LEADERS, EXPERTS, AND CULTURAL ICONS CONVENE AT THE MILKEN INSTITUTE ASIA SUMMIT TO CELEBRATE A TRANSFORMED WORLD

Bank of Baroda rolls out 'Khushiyon ka Tyohaar' as the Festive Season begins

XCMG New Port Machinery's High-end Intelligent Industrial Development Project Base Launches Production

NATIONAL INSTITUTE FOR HEALTH AND CARE RESEARCH CONDUCTS A GLOBAL ANNUAL MEETING TO ADDRESS RESEARCH IN SURGERY IN INDIA

DEAKIN UNIVERSITY HUBS to be set up in India at OP Jindal Global University, Symbiosis International University and Chitkara University

TargEDys and Inoliva announce they have entered a distribution partnership to bring Satylia® to Turkey

Top 50 Start-ups Bringing Innovation to the Global Homes and Buildings Industry

How Healthcare Organizations Can Enhance a Holistic Patient and Member View by Improving Insights from Data

Tata AIA Life Fortune Guarantee Pension gets a powerful upgrade

PDRL aims to certify 10,000+ candidates on AeroMegh Platform in the Drone Industry by the year 2024

DAZN ACCELERATES GLOBAL GROWTH MOMENTUM WITH ACQUISITION OF ELEVEN GROUP BUSINESSES

GoingZero Big Diwali Sale: Up to 40% Discount And Free Shipping On Zero Waste Products

Slow-fashion brand FREECULTR becomes the official merchandise partner for FIFA 2022™

Purple Quarter Facilitates HCAH's CTO, Ex-DealShare Techie Onboarded

Ghodawat Consumer awarded - Fastest growing FMCG Company of 2022

Cine Star Cricket League launched with television and entertainment industry's Divas

ELLE FANNING IS THE AMBASSADOR OF FAME, PACO RABANNE'S NEW FEMININE FRAGRANCE

Saudi Data, AI Authority (SDAIA) and Ministry of Energy Partner with IBM to Accelerate Sustainability Initiatives in Saudi Arabia Using AI

Unstoppable Women of Web3 Launches New Education Streams

PNAS Partners with Straive for Production Services

MOBILEUM convenes the region's leading telecom operators at WEMEET ASIA 2022

Bizverse has officially become a Meta long-term strategic partnership

STL divests IDS as a part of its ongoing portfolio realignment

Frost & Sullivan Honors Tampa Electric Company and Warren, Simpson & Butler County Water Districts with Itron Excellence in Resourcefulness Awards

Mindray Showcases Hematology Innovations and Academic Achievements to the World at ISLH 2022

Deepak Chopra & Seva.Love Announce "ChopraVerse: House of Enlightenment," the Metaverse for Wellbeing in Collaboration with Utopia

MSC TO DEVELOP AIR CARGO SOLUTION IN RESPONSE TO MARKET DEMAND

Harpercollins is proud to announce the upcoming release of The Anarchist Cookbook: A Toolkit to Protest and Peaceful Resistance by Aakar Patel Illustrations by PenPencilDraw

Saudi Arabia launches Nusuk, an integrated digital platform, to facilitate pilgrim journeys for visitors from around the world

MEIL's wholly owned subsidiary MeghaGas, now MCGDPL, to execute City Gas Distribution

Yabx emerges as a leader in digital lending platforms at the top Global Fintech Awards

FII Institute reveals the world's top priority is the rising cost of living

All about IBSAT - One of the Top MBA Entrance Exams in India

MAPIC India 2022 honors India's most admired retail and tech innovators at the MAPIC India Retail Awards

Hasiru Dala Innovations joins forces with Satma CE to give immutable waste traceability from collection to final product made from waste

Bank of Baroda launches Baroda Tiranga Deposits

Alicon Castalloy Limited wins large, multi-year order from Jaguar Land Rover for eMobility Platform

mCaffeine's Biggest Body Care Launch Gets an Overwhelming Response from the Audience: 1 Consumer Subscribed Every 3 Seconds for the Launch

On World Lung Day, Alkem Laboratories pledge to spread awareness about lung diseases through its initiative 'The Healthy Lungs'

LONGi is to showcase its award-winning Hi-MO 5 Series at the Renewable Energy India Expo 2022, unveiling its new Hydrogen Business exclusively for Indian customers

LEXUS INDIA ANNOUNCES MENTORS FOR THE LEXUS DESIGN AWARD INDIA 2023

Mane Kancor CEO Geemon Korah hailed as one of the best CEO's in India

SVKM's NMIMS signs an MoU with HTWG Konstanz, Germany, for short study and research

Top HR Chiefs from TTK Prestige, Silicon Labs, Virtusa, Bureau Veritas at Woxsen's Global HR Leadership Conclave 2022

Mastercard expands decades-long football legacy through GUINNESS WORLD RECORDS™ title with Luis Figo

Soroco and Whatfix Announce Strategic Partnership

ElevenEs produces a prototype of the largest LFP battery cell in Europe

SHEIN CELEBRATED "ROCK THE RUNWAY: SHEIN FOR ALL", ITS FW22 FASHION SHOW

Huawei Hosts the 9th Global Rail Summit in Berlin

Campus With A Conscience hosts a-week long SDG festival

Woxsen University spearheading the internationalisation of higher education in the region through brand new initiatives

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Telangana Police officers paid over Rs 2...
Ankita murder case: Accused Pulkit Arya'...
One held in Ahmedabad for helping ISI op...
Uddhav vs Shinde: SC allows EC to decide...
DRDO conducts successful test flight of ...
YouTuber held for creating memes of Mama...
More...    
 
 Top Stories
FAIMA writes to AIIMS director over... 
3rd ODI: India A hammer New Zealand... 
KCR will play key role in shaping c... 
Over 8 lakh viewers watched SC's fi... 
Pak-US ties no longer hyphenated wi... 
Delhi court grants bail to MCD offi... 
R'than crisis: Cong serves show-cau... 
National Games: Haryana, Bihar, Odi...